Gregg Sherman, MD
Chief Medical Officer, NACE
Deborah Paschal, CRNP
Clinical Nurse Practitioner
Cardiothoracic Surgery Division
Penn-Presbyterian Medical Center
Kilbride Associates Healthcare Communications
San Francisco, CA
Sam Grossman, PharmD, CDE
Corporate Chair GSADE, Primary Care
Clinic in the Manhattan VA
Diabetes Educator at the Department of
New York Harbor Health Care System
New York, NY
Louis Kuritzky, MD
Family Medicine Residency Program
Palms Medical Group
North Florida Regional Medical Center
Clinical Assistant Professor Emeritus
Department of Community Health and Family Medicine
University of Florida
Gary Scheiner, MS, CDE
2014 AADE Diabetes Educator of the Year
Owner & Clinical Director, Integrated Diabetes Services LLC
Jeff Unger, MD, ABFM, FACE
Director, Unger Primary Care Medical Group
Rancho Cucamonga, CA
||Postprandial Hyperglycemia and GLP-1 Receptor Agonists: Effective Strategies to Achieve Goals
||Feb 27 2017
||Feb 26 2018
||Primary Care Providers
||1.0 AMA PRA Category I Credit(s)
1.0 AANP Contact hour(s) which includes 0.75 pharmacology hour(s)
| (Chrome not supported at this time)
The overriding goal of managing patients with T2DM is to safely maintain glycemic control and most patients will require combination therapy with multiple agents. Until recently, pharmacologic options for T2DM included oral antihyperglycemic agents (eg, metformin, sulfonylureas, thiazolidinediones) and insulin (basal, prandial). In the last decade, a new class of agents based on the incretin pathway has emerged as a safe and effective option for many patients with T2DM. The incretin therapeutics include the oral DPP-4 inhibitors, which have moderate glucose-lowering efficacy, and the injectable GLP-1 receptor agonists (RA), which have potent glucose-lowering efficacy and can be safely combined with other medications, including basal insulin. These agents effectively target both fasting and postprandial hyperglycemia, do not cause weight gain, and have low risk for hypoglycemia.
In this monograph, we will review the goals of therapy in T2DM, the frequent need for combination therapy, and the efficacy and safety of GLP-1 RAs, alone and combined with basal insulin.
After completing this program participants should be able to:
- Recognize the role of postprandial hyperglycemia in type 2 diabetes (T2DM) patients not at target and examine its role in the pathogenesis of diabetic complications.
- Utilize glucagon-like peptide (GLP)-1 receptor agonist (GLP-1 RA) therapy to address post-prandial hyperglycemia in ways current strategies do not.
- Compare GLP-1 RAs for glycemic efficacy and differential impact on postprandial glycemic control.
- Discuss various GLP-1 RA combination strategies to effectively control fasting and post-prandial hyperglycemia.
How To Obtain Your CME Certificate 1. Register for the course at www.naceonline.com.
2. View the content.
3. Complete and submit the post-test and evaluation.
4. A minimum passing score of 80% must be earned on the post-test in order to complete the CME
5. Print your CME certificate.
National Association for Continuing Education
|Accreditation Designation Statement
The National Association for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The National Association for Continuing Education designates this enduring activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should only claim the credit commensurate with the extent of their participation in the activity.
National Association for Continuing Education is approved as a provider of nurse practitioner continuing education by the American Association of Nurse Practitioners. AANP Provider Number 121222. This program has been approved for 1.0 contact hour of continuing education(which includes 0.75 pharmacology hours).
Policy on Faculty and Provider Disclosure: It is the policy of the National Association for Continuing Education to ensure fair balance, independence, objectivity and scientific rigor in all activities. All faculty participating in CME activities sponsored by the National Association for Continuing Education are required to present evidence-based data, identify and reference off-label product use and disclose all relevant financial relationships with those supporting the activity or others whose products or services are discussed. Faculty disclosures are provided below.
Sam Grossman, PharmD, CDE, Faculty, has no relationships to disclose.
Louis Kuritzky, MD, Faculty, serves as an advisor, consultant, or speaker for Boehringer Ingelheim, Sanofi, Salix, AbbVie, Allergan, Lilly, Lundbeck, Novo Nordisk, and Janssen.
Gary Scheiner, MS, CDE, Faculty, serves as a speaker for Novo Nordisk, Dexcom, and Insulet. He serves on the advisory boards of Ascensia (Bayer), Diasend, BD, and Convatec. He is also a trainer/speaker for Tandem and a consultant for Mysugr.
Jeff Unger, MD, ABFM, FACE, Faculty, serves as a speaker, stock owner, consultant and researcher for Novo Nordisk. He is also a speaker for Janssen and Teva.
Gregg Sherman, MD, Co-Course Director, has no relationships to disclose.
Deborah Paschal, CRNP, Co-Course Director, has no relationships to disclose.
Josh Kilbridge, Medical Writer, has no relationships to disclose.
Harvey C. Parker, Ph.D., Activity Planning Committee, has no relationships to disclose.
Michelle Frisch, MPH, Activity Planning Committee, has no relationships to disclose.
Alan Goodstat, LCSW, Activity Planning Committee, has no relationships to disclose.
Cheryl C. Kay, Activity Planning Committee, has no relationships to disclose.
This activity is supported by an educational grant from Sanofi US.